Relay Therapeutics, Inc. (RLAY) is a publicly traded company in the Unknown sector. Across all available filings, 16 corporate insiders have executed 278 transactions totaling $257.8M, demonstrating a bearish sentiment with -$253.4M in net insider flow. The most recent transaction on Nov 3, 2025 involved a sale of 62,073 shares valued at $434.5K.
No significant insider buying has been recorded for RLAY in the recent period.
No significant insider selling has been recorded for RLAY in the recent period.
Based on recent SEC filings, insider sentiment for RLAY is bearish with an Insider Alignment Score of 1/100 and a net flow of -$253.4M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Relay Therapeutics, Inc. (RLAY) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 16 insiders are actively trading RLAY stock, having executed 278 transactions in the past 90 days. The most active insider is Robert I. Tepper (Executive), who has made 12 transactions totaling $227.1M.
Get notified when executives and directors at RLAY file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Nov 3, 2025 | Patel Sanjiv | Executive | Sale | 62,073 | $7.00 | $434.5K | |
| Oct 29, 2025 | Rahmer Peter | Executive | Sale | 21,394 | $7.50 | $160.5K | |
| Oct 28, 2025 | A. Bergstrom Donald | Executive | Sale | 30,897 | $7.29 | $225.2K | |
| Oct 28, 2025 | Catinazzo Thomas | Executive | Sale | 21,664 | $7.29 | $157.9K | |
| Oct 28, 2025 | Rahmer Peter | Executive | Sale | 19,135 | $7.29 | $139.5K | |
| Jul 29, 2025 | Adams Brian | Executive | Sale | 18,276 | $3.68 | $67.3K | |
| Jul 29, 2025 | A. Bergstrom Donald | Executive | Sale | 26,701 | $3.68 | $98.3K | |
| Jul 29, 2025 | Catinazzo Thomas | Executive | Sale | 18,380 | $3.68 | $67.6K | |
| Jul 29, 2025 | Rahmer Peter | Executive | Sale | 15,724 | $3.68 | $57.9K | |
| Jul 28, 2025 | Adams Brian | Executive | Sale | 1,637 | $3.74 | $6.1K | |
| Jul 28, 2025 | A. Bergstrom Donald | Executive | Sale | 4,069 | $3.74 | $15.2K | |
| Jul 28, 2025 | Catinazzo Thomas | Executive | Sale | 1,701 | $3.74 | $6.4K | |
| Jul 28, 2025 | Rahmer Peter | Executive | Sale | 1,359 | $3.74 | $5.1K | |
| Jul 9, 2025 | Patel Sanjiv | Executive | Sale | 42,740 | $3.57 | $152.6K | |
| Jul 9, 2025 | Patel Sanjiv | Executive | Sale | 18,639 | $3.57 | $66.5K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 179 | $255.6M | 97.7% |
Exercise(M) | 51 | $3.8M | 1.4% |
Purchase(P) | 5 | $2.2M | 0.8% |
Award(A) | 25 | $124.0K | 0.0% |
Gift(G) | 5 | $0 | 0.0% |
Other(J) | 3 | $0 | 0.0% |
Conversion(C) | 10 | $0 | 0.0% |
Insider selling pressure at Relay Therapeutics, Inc. has increased, with 16 insiders executing 278 transactions across all time. Total sales of $255.6M significantly outpace purchases of $2.2M, resulting in a net outflow of $253.4M. This selling activity appears largely discretionary, which may warrant closer attention from investors.